









Markets
/
Stocks
/
nasdaq-cybn
/

Cybin Inc

CYBN

8.280USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

216.12MMarket Cap

LossP/E TTM



Cybin Inc

8.280

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cybin Inc

Currency: USD Updated: 2026-01-02

Key Insights

Cybin Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 55 out of 403 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 58.17.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cybin Inc's Score

Industry at a Glance

Industry Ranking

55 / 403

Overall Ranking

175 / 4550

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cybin Inc Highlights

StrengthsRisks

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -2.11, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.70M shares, decreasing 83.66% quarter-over-quarter.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

53.000

Target Price

+733.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-02

The current financial score of Cybin Inc is 7.45, ranking 117 out of 403 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

0.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.91

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

6.91

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cybin Inc's Company Valuation

Currency: USD Updated: 2026-01-02

The current valuation score of Cybin Inc is 7.33, ranking 142 out of 403 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.11, which is -39.13% below the recent high of -1.29 and -6307.27% above the recent low of -135.26.

Score

Industry at a Glance

Previous score

0.00

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 55/403

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-02

The current earnings forecast score of Cybin Inc is 8.29, ranking 143 out of 403 in the Biotechnology & Medical Research industry. The average price target is 51.50, with a high of 114.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

53.000

Target Price

+733.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Cybin Inc

CYBN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-02

The current price momentum score of Cybin Inc is 8.90, ranking 40 out of 403 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.73 and the support level at 6.22, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.303

Buy

RSI(14)

69.147

Neutral

STOCH(KDJ)(9,3,3)

69.162

Sell

ATR(14)

0.521

Low Volatility

CCI(14)

71.864

Neutral

Williams %R

30.325

Buy

TRIX(12,20)

1.446

Sell

StochRSI(14)

7.894

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

8.416

Sell

MA10

7.921

Buy

MA20

7.093

Buy

MA50

6.565

Buy

MA100

6.495

Buy

MA200

6.943

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-02

Score

Industry at a Glance

Previous score

0.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

VR Adviser, LLC

3.84M

Tang Capital Management, LLC

1.83M

Rosalind Advisors, Inc.

1.50M

+84.98%

Tziras (George)

1.29M

Point72 Asset Management, L.P.

Star Investors

1.24M

-22.83%

Deep Track Capital LP

1.00M

Bartlone (Aaron Frank)

901.07K

+28.53%

Acorn Capital Advisors, LLC

734.39K

Fahel (Gabriel)

405.35K

+0.54%

Sphera Funds Management Ltd.

370.38K

-7.01%

Risk Assessment

Currency: USD Updated: 2026-01-02

The current risk assessment score of Cybin Inc is 3.80, ranking 129 out of 403 in the Biotechnology & Medical Research industry. The company's beta value is 0.13. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.